Aromataze inhibitors in the treatment of breast cancer
Journal Title: OncoReview - Year 2012, Vol 2, Issue 3
Abstract
The main goal for hormonal therapy of breast cancer is to inhibit action of endogenous estrogens to breast cancer cells. Discovery of hormonal receptors and knowledge of their biological role employment to manner hormonal treatment as target therapy. Postmenopausal estrogens are synthesized from androgens, mainly androstenedione, which is converted into estrone. Aromatase inhibitors potently inhibit aromatase activity and also suppress estrogen levels in plasma and tissue. Aromatase inhibitor are safety and convenient drugs In clinical studies in postmenopausal women with breast cancer shown superior to tamoxifen for the treatment of metastatic disease, and in neoadjuvant approach Studies of adjuvant therapy with aromatase inhibitors include: head-to-head studies of the aromatase inhibitor versus tamoxifen monotherapy, sequential therapy of 2–3 years of tamoxifen followed by an aromatase inhibitor (or the opposite sequence) versus 5 years of tamoxifen monotherapy: extended therapy with an aromatase inhibitor after 5 years of tamoxifen. Aromatase inhibitors are active and are recommended in every stage of breast cancer.
Authors and Affiliations
Tadeusz Pieńkowski
Keywords
Related Articles
- EP ID EP53166
- DOI -
- Views 230
- Downloads 0
Leczenie nadpłytkowości samoistnej w ciąży - doświadczenia własne ośrodka
Nadpłytkowość samoistna (ET) jest przewlekłym nowotworem mieloproliferacyjnym dotyczącym głównie linii megakariocytów, przebiegającym ze zwiększoną ponad 450 000/ul liczbą płytek krwi. Nadpłytkowość występuje przede wszy...
Nowe spojrzenie na ocenę skuteczności terapii celowanych zaawansowanego raka nerki– kontrowersje
W ciągu ostatnich kilku lat daje się zaobserwować zdecydowany rozwój nowoczesnych terapii stosowanych w leczeniu zaawansowanego/ rozsianego raka nerki, związany przede wszystkim z poznaniem podstaw molekularnych raka ner...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...
Mindfulness in the treatment of chronic pain and improvement in the quality of life of both oncological and non-oncological patients
Pain, which accompanies almost every third Pole, is an ever greater medical, psychological and social challenge. Relieving pain, and chronic one in particular, is now becoming one of the most important tasks for contempo...
Acute coronary syndrome in patients with concomitant neoplastic disease and chemotherapy. Is clinical distinctness possible?
We present 2 cases of acute coronary syndrome in patients with concomitant neoplastic disease during chemotherapy. In both patients, we found unusual angiographic image which showed that despite the presence of very larg...